Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQT study of danicopan in healthy adults
NCT05016206Phase 1Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Jul 2018
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of danicopan in paroxysmal nocturnal hemoglobinuria (PNH) (2 arms), sponsored by Alexion Pharmaceuticals. Primary endpoint: Placebo-corrected Change From Baseline In QTc Intervals (ddQTc) For Danicopan. Started Jul 2018; status: completed.
02
Drugs
danicopan
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on NCT05016206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05016206.